Vertex Pharmaceuticals is suing the U.S. Department of Health and Human Services, aiming for a court declaration that a fertility support program for patients who are prescribed the company’s Casgevy does not break federal anti-kickback laws, Reuters reports. The gene editing therapy has been approved for the treatment of sickle cell disease and transfusion-dependent beta-thalassemia in the U.S., the report notes.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRTX:
- Vertex Pharmaceuticals CMO Bozic sells 2,280 common shares
- Vertex Pharmaceuticals price target raised to $455 from $402 at Morgan Stanley
- Vertex Pharmaceuticals announces FDA acceptance of triple combination therapy
- Verve Therapeutics appoints Nia Tatsis, Jodie Morrison to board
- Dynatrace initiated, U.S. Bancorp downgraded: Wall Street’s top analyst calls